子宫内膜透明细胞癌的分子亚型:预后与预测分层的机会
本研究对52例子宫内膜透明细胞癌(CCC)进行ProMisE分子分型,分为POLEmut、MMRd、p53wt和p53abn四个亚型,并评估临床病理参数、免疫标志物和结局。结果发现CCC涵盖所有四种分子亚型,其中p53wt CCC在临床病理特征和结局上不同于p53wt子宫内膜样癌,提示其为一个独特的临床病理实体。
要点
- CCC可分为POLEmut、MMRd、p53wt和p53abn四个分子亚型。
- p53wt CCC与p53wt子宫内膜样癌不同,预后更差。
- CCC中常见高免疫浸润,L1CAM过表达多见于p53abn和p53wt亚型。
核心结论
- CCC是一种异质性疾病,包含所有四种分子亚型且临床结局差异大。
- POLEmut、MMRd和p53abn CCC的结局与其他EC相应亚型患者无法区分。
- p53wt CCC在临床、病理、分子特征和结局上不同于p53wt子宫内膜样EC,可能是一个独特的临床病理实体。
研究设计与样本
- 对52例子宫内膜透明细胞癌(CCC)进行ProMisE分子分型。
- 评估临床病理参数、免疫标志物(CD3、CD8、CD79a、CD138、PD-1)、ER、L1CAM和结局。
主要发现
- 52例CCC中,POLEmut 1例(2%),MMRd 5例(10%),p53wt 28例(54%),p53abn 18例(35%)。
- p53abn和p53wt CCC患者年龄大于MMRd和POLEmut亚型患者。
- p53wt CCC更常见于年老、较瘦女性,分期晚,有LVSI和淋巴结受累,ER阴性比例高,L1CAM过表达,结局显著更差。
- 75%的CCC cohort观察到高免疫浸润(TILhigh)。
- L1CAM过表达在p53abn和p53wt亚型中最高。
临床怎么用
- 对CCC进行分子分型有助于预后分层和预测。
- p53wt CCC应被视为不同于p53wt子宫内膜样癌的实体,需更密切管理。
局限性
- 样本量较小(52例),需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our aim was to characterize the pathological, molecular and clinical outcomes of clear cell carcinoma of the endometrium (CCC). METHODS: CCC underwent ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) classification identifying four molecular subtypes: i) 'POLEmut' for ECs with pathogenic POLE mutations, ii) 'MMRd', if there is loss of mismatch repair proteins by immunohistochemistry (IHC), iii) 'p53wt' or iv) 'p53abn' based on p53 IHC staining. Clinicopathologic parameters, immune markers (CD3, CD8, CD79a, CD138, PD-1), ER, L1CAM, and outcomes were assessed. RESULTS: 52 CCCs were classified, including 1 (2%) POLEmut, 5 (10%) MMRd, 28 (54%) p53wt and 18 (35%) p53abn. Women with p53abn and p53wt CCCs were older than women with MMRd and POLEmut subtypes. p53wt CCC were distinct from typical p53wt endometrioid carcinomas; more likely to arise in older, thinner women, with advanced stage disease, LVSI and lymph node involvement, and a higher proportion ER negative, L1CAM overexpressing tumors with markedly worse outcomes. High levels of immune infiltrates (TILhigh) were observed in 75% of the CCC cohort. L1CAM overexpression was highest within p53abn and p53wt subtypes of CCC. CONCLUSION: CCC is a heterogeneous disease encompassing all four molecular subtypes and a wide range of clinical outcomes. Outcomes of patients with POLEmut, MMRd and p53abn CCC are not distinguishable from those of other patients with these respective subtypes of EC; p53wt CCC, however, differ from endometrioid p53wt EC in clinical, pathological, molecular features and outcomes. Thus, p53wt CCC of endometrium appear to be a distinct clinicopathological entity within the larger group of p53wt ECs.
引用
- Kim SR, Cloutier BT, Leung S, et al. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. Gynecol Oncol. 2020. PMID: 32331700. doi:10.1016/j.ygyno.2020.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。